

MAY 09 2008

Appl. No. 09/714,351
Amendment dated May 9, 2008
Supplement to Response of Feb. 4, 2008

Amendments to the Claims:


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) Atorvastatin calcium Form V ~~of claim 3~~ according to any one of claims 2, 4, 5 or 17 produced by a process comprising the steps of

- a) dissolving a metal, ammonium or alkylammonium salt of atorvastatin in a solvent to form an atorvastatin salt solution,
- b) contacting the atorvastatin salt solution with a calcium salt, and
- c) isolating atorvastatin calcium Form V.


2. (Currently amended) Atorvastatin calcium Form V having an X-ray powder diffractogram substantially as follows depicted in Figure 1.



3. (Previously presented) Atorvastatin calcium Form V characterized by X-ray powder diffraction peaks at 5.3 ± 0.2 and 8.3 ± 0.2 degrees 2θ and a broad peak at $18-23 \pm 0.2$ degrees 2θ with a maximum at 18.3 ± 0.2 degrees 2θ .

Appl. No. 09/714,351
Amendment dated May 9, 2008
Supplement to Response of Feb. 4, 2008

4. (Currently amended) Atorvastatin calcium Form V having a solid state ^{13}C NMR spectrum substantially as follows depicted in Figure 2.



5. (Previously presented) Atorvastatin calcium Form V characterized by solid state ^{13}C NMR signals at 21.9, 25.9, 118.9, 122.5, 128.7, 161.0 and 167.1 ppm.

6-16. (Canceled)

17. (Currently amended) Atorvastatin calcium Form V characterized by X-ray powder diffraction peaks at 5.3 ± 0.2 and 8.3 ± 0.2 degrees 2θ and solid state ^{13}C NMR signals at 21.9, 25.9, 118.9, 122.5, 128.7, 161.0 and 167.1 ppm.

18-19. (Canceled)